Neuroendocrine Tumours Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

June 2026 | - | ID: N0E8E2ECF9B1EN
BIS Research Inc.

Abstracts

The global Neuroendocrine Tumours (NETs) market is in the growth phase, driven by significant advancements in both diagnostic capabilities and treatment modalities. The increasing prevalence of Neuroendocrine Tumours, particularly with improved detection through technologies such as PET/CT scans and biomarker-based diagnostics, is expanding the patient base.

At the same time, the market is benefiting from innovations in targeted therapies like Peptide Receptor Radionuclide Therapy (PRRT), somatostatin analogs, and the growing potential of immunotherapies and radiopharmaceuticals. This growth is further accelerated by the development of precision medicine tailored to the genetic and molecular profiles of Neuroendocrine Tumours, along with increased research funding and regulatory support for rare diseases. As a result, pharmaceutical companies are expanding their clinical pipelines and entering into strategic partnerships, positioning the market for continued expansion in the coming years.

Market Segmentation:

Segmentation 1 - By Region

• North America
• Europe
• Asia-Pacific
• Rest-of-the-World

North America dominates the global Neuroendocrine Tumours (NETs) market due to several key factors, including advanced healthcare infrastructure, high treatment accessibility, and strong reimbursement frameworks that facilitate the adoption of cutting-edge therapies. The region benefits from a well-established presence of major pharmaceutical companies such as Ipsen, Novartis, and Merck, which have developed and marketed leading therapies like somatostatin analogs and Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumours.

Furthermore, increased awareness and early diagnosis driven by advanced imaging technologies, such as PET/CT scans, contribute to higher detection rates, allowing for timely interventions. Additionally, North America boasts robust research and development (R&D) investments, leading to continuous innovations in targeted treatments, immunotherapies, and radiopharmaceuticals. Regulatory support for orphan drug treatments and clinical trial funding further accelerates market growth, making the region a critical hub for both the development and consumption of NET therapies. These factors collectively reinforce North America’s dominant position in the global Neuroendocrine Tumours market.

Demand – Drivers and Limitations

Demand drivers for the Global Neuroendocrine Tumours Market:

• Increasing Prevalence of Neuroendocrine Tumours:

The rising incidence of neuroendocrine tumours, particularly due to improved diagnostic technologies, is a key driver of demand. With better detection methods, such as PET/CT scans and biomarker-based diagnostics, more patients are being diagnosed, leading to an increased need for effective treatments.

• Advancements in Diagnostic Technologies:

The development of cutting-edge diagnostic tools, including imaging techniques and genetic profiling, has led to earlier detection of Neuroendocrine Tumours, which enables timely intervention and long-term management, thus expanding the patient base.

• Improved Treatment Modalities:

The advent of targeted therapies (such as Peptide Receptor Radionuclide Therapy (PRRT)), radiopharmaceuticals, somatostatin analogs (e.g., lanreotide and octreotide), and immunotherapies has significantly improved treatment options for NET patients, making the condition more manageable and thereby increasing the demand for these therapies.

Limitations for the Global Neuroendocrine Tumours Market:

• High Cost of Treatment:

Treatments for Neuroendocrine Tumours, especially radiopharmaceuticals like PRRT and innovative biologics, can be expensive. The cost burden associated with these therapies often limits access, particularly in developing countries or regions with less comprehensive healthcare systems. High costs can also strain healthcare systems and insurance providers.

• Limited Awareness in Low-Income Regions:

Despite growing awareness in developed markets, Neuroendocrine Tumours remain underdiagnosed and less understood in low-income regions and rural areas. This limited awareness and access to healthcare contribute to delayed diagnoses and limited treatment options, hindering demand in these regions.

How can this report add value to an organisation?

Product/Innovation: Adjunct pharmacological therapies play a vital role in the management of Neuroendocrine Tumours (NETs), particularly for patients with advanced or metastatic disease who may not be candidates for surgery. Somatostatin analogs, such as Octreotide and Lanreotide, are commonly used to control symptoms like carcinoid syndrome and slow tumor growth by inhibiting hormone secretion. Targeted therapies, including Tyrosine Kinase Inhibitors (TKIs) like Everolimus and Sunitinib, are used in advanced stages to target molecular pathways driving tumor growth, while chemotherapy is reserved for high-grade, poorly differentiated Neuroendocrine Tumours.

Additionally, radiopharmaceuticals such as Lutetium-177-based PRRT are emerging as powerful treatments for metastatic Neuroendocrine Tumours, delivering targeted radiation to tumors. Immunotherapies, though still in clinical trials, show promise in treating aggressive, high-grade NETs by boosting the body’s immune response against cancer cells. Finally, palliative care and symptom management, including pain relief and hormone control, are crucial for improving the quality of life in patients with advanced disease. As treatment options evolve, the integration of these adjunct therapies is enhancing overall survival rates and patient well-being, making a significant impact on the management of Neuroendocrine Tumours.

Growth/Marketing: The report examines regional demand, patient demographics, and adoption barriers in Neuroendocrine Tumours (NETs) therapeutics, offering valuable insights to understand the dynamics of the global market. By analyzing regional variations in disease prevalence and healthcare access, the report highlights key differences in the adoption of Neuroendocrine Tumours therapies across regions like North America, Europe, Asia-Pacific, and Latin America. It identifies patient demographics, focusing on factors such as age, gender, and underlying comorbidities, which influence treatment approaches and therapeutic choices. The report also delves into the adoption barriers that impact market growth, including high treatment costs, limited access to specialized healthcare, and diagnostic delays in low-income or rural regions. Furthermore, it explores how healthcare infrastructure, insurance coverage, and regulatory frameworks affect the availability and utilization of NET therapeutics. These insights help pharmaceutical companies, healthcare providers, and policymakers understand the diverse challenges and opportunities in the Neuroendocrine Tumours market, enabling them to make informed decisions and tailor strategies for global market penetration, targeted treatment plans, and improved patient outcomes.

Competitive: The report provides a comprehensive profiling of key players in the Neuroendocrine Tumours (NETs) therapeutics market, offering detailed insights into their pipeline strategies, partnerships, and R&D initiatives. By examining the ongoing research and development efforts, the report highlights the most promising drug candidates and therapeutic approaches under investigation by leading companies in the Neuroendocrine Tumours space. This includes targeted therapies, radiopharmaceuticals, and immunotherapies that are advancing through the clinical trial stages.

Additionally, the report outlines the strategic partnerships formed between pharmaceutical companies, academic institutions, and research organizations, which are key drivers for accelerating innovation and expanding market reach. It also analyzes how collaborations, such as those seen in radiopharmaceuticals (e.g., PRRT) and targeted therapies (e.g., somatostatin analogs), are shaping the competitive landscape.

By providing competitive benchmarking, the report offers a comparative analysis of the market positions and capabilities of major players, identifying strengths and weaknesses. This allows stakeholders to understand market trends, assess investment opportunities, and make strategic decisions that are critical for expanding market share, entering new regions, and developing breakthrough therapies. The insights help investors, pharma executives, and healthcare providers to navigate the dynamic and competitive NETs market effectively, ensuring long-term growth and sustained innovation.

Key Market Players and Competitive Landscape

The pharmaceutical companies engaged in developing and marketing therapeutic interventions for Neuroendocrine Tumours (NETs) are making significant strides in advancing treatment options for this complex and rare cancer. Key players such as Ipsen, Novartis, and Merck dominate the market with established therapies, including somatostatin analogs like Somatuline and Octreotide, which help control symptoms and inhibit tumor growth.

Additionally, Advanced Accelerator Applications (a Novartis subsidiary) has positioned itself as a leader in Peptide Receptor Radionuclide Therapy (PRRT), using Lutetium-177 for targeted therapy in advanced Neuroendocrine Tumours. Meanwhile, emerging companies like Lantheus Holdings (formerly Progenics Pharmaceuticals) are focusing on radiopharmaceuticals such as Azedra, which treats pheochromocytoma and paraganglioma, rare forms of Neuroendocrine Tumours.

The market is also witnessing growing interest in immunotherapy, gene-based therapies, and radioligand therapies, with companies like Crinetics Pharmaceuticals, RayzeBio, and Chimerix exploring novel approaches to treat Neuroendocrine Tumours. This landscape is further enriched by efforts from Pfizer, BMS, and Shionogi, who are developing targeted therapies and immuno-oncology treatments. As the market for Neuroendocrine Tumours continues to expand, these companies are shaping the future of treatment through innovations in precision medicine, combination therapies, and advancements in diagnostics.

The increasing collaboration between these industry leaders, alongside acquisitions and partnerships, is expected to drive progress in providing more effective and personalized treatments for patients with neuroendocrine tumors.

Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.

This report will be delivered in 2 working days.

Contents

Executive Summary
Scope of Study
Definition
Inclusion and Exclusion Criteria

1. GLOBAL NEUROENDOCRINE TUMOURS MARKET: INDUSTRY OUTLOOK

1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis
  1.2.1 U.S.
  1.2.2 EU
    1.2.2.1 Germany
    1.2.2.2 France
  1.2.3 Rest-of-the-World
1.3 Market Trends
1.4 Clinical Trial Analysis
1.5 Regulatory Landscape Analysis
  1.5.1 Legal Requirement and Framework in U.S.
  1.5.2 Legal Requirement and Framework in E.U.
  1.5.3 Legal Requirement and Framework in Asia-Pacific
  1.5.4 Legal Requirement and Framework in Rest-of-the-World
1.6 Market Dynamics
  1.6.1 Impact Analysis
  1.6.2 Market Drivers
  1.6.3 Market Restraints
  1.6.4 Market Opportunities

2. GLOBAL NEUROENDOCRINE TUMOURS MARKET, BY REGION, $MILLION, 2024-2035

2.1 North America
  2.1.1 Key Findings
  2.1.2 Market Dynamics
  2.1.3 Market Sizing and Forecast
    2.1.3.1 North America Neuroendocrine Tumours Market (by Country)
      2.1.3.1.1 U.S.
      2.1.3.1.2 Canada
2.2 Europe
  2.2.1 Key Findings
  2.2.2 Market Dynamics
  2.2.3 Market Sizing and Forecast
    2.2.3.1 Europe Neuroendocrine Tumours Market (by Country)
      2.2.3.1.1 Germany
      2.2.3.1.2 France
      2.2.3.1.3 Italy
      2.2.3.1.4 Spain
      2.2.3.1.5 U.K.
      2.2.3.1.6 Rest-of-Europe
2.3 Asia-Pacific
  2.3.1 Key Findings
  2.3.2 Market Dynamics
  2.3.3 Market Sizing and Forecast
    2.3.3.1 Asia-Pacific Neuroendocrine Tumours Market (by Country)
      2.3.3.1.1 Japan
      2.3.3.1.2 Rest-of-Asia-Pacific
2.4 Rest-of-the-World
  2.4.1 Key Findings
  2.4.2 Market Dynamics
  2.4.3 Market Sizing and Forecast

3. GLOBAL NEUROENDOCRINE TUMOURS MARKET: COMPETITIVE BENCHMARKING AND COMPANY PROFILES

3.1 Competitive Benchmarking
3.2 Competitive Landscape
  3.2.1 Key Strategies and Developments by Company
    3.2.1.1 Funding Activities
    3.2.1.2 Mergers and Acquisitions
    3.2.1.3 Regulatory Approvals
    3.2.1.4 Partnerships, Collaborations, and Business Expansions
  3.2.2 Key Developments Analysis
3.3 Company Profiles
  3.3.1 Merck
    3.3.1.1 Company Overview
    3.3.1.2 Product Portfolio
    3.3.1.3 Target Customers/End Users
    3.3.1.4 Key Personnel
    3.3.1.5 Analyst View
  3.3.2 Lantheus Holdings (Progenics Pharmaceuticals)
    3.3.2.1 Company Overview
    3.3.2.2 Product Portfolio
    3.3.2.3 Target Customers/End Users
    3.3.2.4 Key Personnel
    3.3.2.5 Analyst View
  3.3.3 Fujifilm Toyama Chemical
    3.3.3.1 Company Overview
    3.3.3.2 Product Portfolio
    3.3.3.3 Target Customers/End Users
    3.3.3.4 Key Personnel
    3.3.3.5 Analyst View
  3.3.4 Novartis (Advanced Accelerator Applications S.A.)
    3.3.4.1 Company Overview
    3.3.4.2 Product Portfolio
    3.3.4.3 Target Customers/End Users
    3.3.4.4 Key Personnel
    3.3.4.5 Analyst View
  3.3.5 Ipsen Biopharmaceuticals
    3.3.5.1 Company Overview
    3.3.5.2 Product Portfolio
    3.3.5.3 Target Customers/End Users
    3.3.5.4 Key Personnel
    3.3.5.5 Analyst View
  3.3.6 Shionogi
    3.3.6.1 Company Overview
    3.3.6.2 Product Portfolio
    3.3.6.3 Target Customers/End Users
    3.3.6.4 Key Personnel
    3.3.6.5 Analyst View
  3.3.7 Nippon Kayaku
    3.3.7.1 Company Overview
    3.3.7.2 Product Portfolio
    3.3.7.3 Target Customers/End Users
    3.3.7.4 Key Personnel
    3.3.7.5 Analyst View
  3.3.8 Kyowa Hakko Kirin
    3.3.8.1 Company Overview
    3.3.8.2 Product Portfolio
    3.3.8.3 Target Customers/End Users
    3.3.8.4 Key Personnel
    3.3.8.5 Analyst View
  3.3.9 Pfizer
    3.3.9.1 Company Overview
    3.3.9.2 Product Portfolio
    3.3.9.3 Target Customers/End Users
    3.3.9.4 Key Personnel
    3.3.9.5 Analyst View
  3.3.10 Bausch Health & Ono Pharmaceutical
    3.3.10.1 Company Overview
    3.3.10.2 Product Portfolio
    3.3.10.3 Target Customers/End Users
    3.3.10.4 Key Personnel
    3.3.10.5 Analyst View
  3.3.11 ITM Solucin GmbH
    3.3.11.1 Company Overview
    3.3.11.2 Product Portfolio
    3.3.11.3 Target Customers/End Users
    3.3.11.4 Key Personnel
    3.3.11.5 Analyst View
  3.3.12 Camurus
    3.3.12.1 Company Overview
    3.3.12.2 Product Portfolio
    3.3.12.3 Target Customers/End Users
    3.3.12.4 Key Personnel
    3.3.12.5 Analyst View
  3.3.13 Crinetics Pharmaceuticals
    3.3.13.1 Company Overview
    3.3.13.2 Product Portfolio
    3.3.13.3 Target Customers/End Users
    3.3.13.4 Key Personnel
    3.3.13.5 Analyst View
  3.3.14 Chimerix
    3.3.14.1 Company Overview
    3.3.14.2 Product Portfolio
    3.3.14.3 Target Customers/End Users
    3.3.14.4 Key Personnel
    3.3.14.5 Analyst View
  3.3.15 Perspective Therapeutics
    3.3.15.1 Company Overview
    3.3.15.2 Product Portfolio
    3.3.15.3 Target Customers/End Users
    3.3.15.4 Key Personnel
    3.3.15.5 Analyst View
  3.3.16 Teclison
    3.3.16.1 Company Overview
    3.3.16.2 Product Portfolio
    3.3.16.3 Target Customers/End Users
    3.3.16.4 Key Personnel
    3.3.16.5 Analyst View
  3.3.17 Chimeric Therapeutics
    3.3.17.1 Company Overview
    3.3.17.2 Product Portfolio
    3.3.17.3 Target Customers/End Users
    3.3.17.4 Key Personnel
    3.3.17.5 Analyst View
  3.3.18 Others

4. RESEARCH METHODOLOGY

List Of Figures

LIST OF FIGURES

Figure: Neuroendocrine Tumours Market (by Scenario), $Million, 2024, 2030, and 2035
Figure: Global Neuroendocrine Tumours Market, 2024 and 2035
Figure: Global Neuroendocrine Tumours Market Key Trends, Impact Analysis
Figure: North America Neuroendocrine Tumours Market, $Million, 2024-2035
Figure: Europe Neuroendocrine Tumours Market, $Million, 2024-2035
Figure: Asia-Pacific Neuroendocrine Tumours Market, $Million, 2024-2035
Figure: Rest-of-the-World Neuroendocrine Tumours Market, $Million, 2024-2035

List Of Tables

LIST OF TABLES

Table: Market Snapshot
Table: Market Dynamics
Table: Global Neuroendocrine Tumours Market (by Region), $Million, 2024-2035